Pyridostigmine enhances, but does not normalise, the GH response to GH-releasing hormone in obese subjects.

Pyridostigmine enhances, but does not normalise, the GH response to GH-releasing hormone in obese subjects.

Obese patients are characterised by several neuroendocrine abnormalities, including characteristically a decrease in growth hormone responsiveness to GH-releasing hormone. In normal subjects, the GH response to GHRH is enhanced by the acetylcholinesterase inhibitor, pyridostigmine. We have studied t...

Full description

Bibliographic Details
Main Authors: Castro, R, Vieira, J, Chacra, A, Besser, G, Grossman, AB, Lengyel, A
Format: Journal article
Language:English
Published: 1990

Similar Items

Similar Items